|
Latest News
..........................................
November 6, 2008
Oculus
Innovative Sciences Reports Record Second Quarter Product Revenue Up 81%
November 4, 2008
Oculus
Innovative Sciences to Present at the Rodman & Renshaw 10th Annual Healthcare
Conference on November 11
October 30, 2008
Oculus
Innovative Sciences Announces Fiscal Second Quarter Financial Results and Corporate
Update Release and Conference Call
October 29, 2008
Oculus
Innovative Sciences Introduces Microcyn® Wound Care OTC for U.S. Consumer
Market
October 22, 2008
Oculus
Innovative Sciences Launches Microcyn® Wound Care for U.S. Podiatry Market
October 9, 2008
Oculus
Innovative Sciences Provides Clinical and Business
Update
September 11, 2008
Oculus
Innovative Sciences and Sinopharm Announce Introduction
of Dermacyn™ to Hospitals in China
September 10, 2008
Oculus
Innovative Sciences to Present at the Merriman Curhan
Ford 5th Annual Investor Summit on September 15
September 9, 2008
Oculus
Innovative Sciences Reduces Planned Expenses While Accelerating Global Commercialization
September 4, 2008
Oculus
Innovative Sciences Holds Successful End-of-Phase II Meeting with FDA for Microcyn® Technology
August 7, 2008
Oculus
Innovative Sciences to Present at Canaccord Adams 28th Annual Global Growth
Conference
August 5, 2008
Oculus
Innovative Sciences Reports 59% Increase in First Quarter Product Revenue
July 29, 2008
Oculus
Innovative Sciences Announces Fiscal First Quarter Financial Results and Corporate
Update Release and Conference Call
July 16, 2008
Oculus
Innovative Sciences' CEO and Founder Named One of Pharmaceutical Executive's
2008 "Emerging Pharma Leaders"
July 1, 2008
Oculus
Innovative Sciences Announces Positive Results from Abstract Evaluating the
Use of Microcyn® Technology in Treatment of Atopic Dermatitis
June 23, 2008
Oculus
Innovative Sciences Announces Agreement With Bayer (Sichuan) Animal Health
Co. Ltd. for Development of Microcyn® Technology Use in Chinese Animal
Market
June 19, 2008
Oculus
Innovative Sciences Announces Agreement with Bayer Australia Limited for
Development of Microcyn® Technology Use in Australian Animal Market
June 17, 2008
Oculus
Innovative Sciences Announces Development of Microcyn®-Based Hydrogel
Formulation
June 16, 2008
Oculus
Innovative Sciences Announces Breakthrough Antimicrobial Formulation for
Over-The-Counter Non-Wound Market to be Launched in U.S. Without Pre-Approval
by the FDA
June 11, 2008
Oculus
Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial
Results and Corporate Update
June 5, 2008
Oculus
Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial
Results and Corporate Update Release and Conference Call
June 4, 2008
Oculus
Innovative Sciences Files for Patent Protection on Breakthrough Wound Care
Device to Accelerate Wound Healing
June 2, 2008
Oculus
Innovative Sciences Announces Market Assessment of Near-Term Commercialization
Opportunities in the United States for Dermacyn™ Wound Care
May 28, 2008
Oculus
Innovative Sciences Announces Publication of Microcyn® Technology Post-Caesarean
Section Wound Study in Indian Medical Gazette
May 15, 2008
Oculus
Innovative Sciences to Participate in Third Congress of the World Union of
Wound Healing Societies in Toronto
May 5, 2008
Oculus
Innovative Sciences Announces Initial Chinese Commercialization Plan for Launch
of Microcyn® Technology
April 23, 2008
Oculus
Innovative Sciences Appoints Michelle Carpenter, JD, RAC, as Vice President
of Regulatory Affairs and Quality
April 17, 2008
Oculus
Innovative Sciences' CEO and Founder Hoji Alimi Featured on NASDAQ CEO Signature
Series
April 15, 2008
Oculus
Innovative Sciences Announces Publication of Microcyn® Technology Diabetic
Wound Study in Journal of College of Physicians and Surgeons Pakistan
March 28, 2008
Oculus
Innovative Sciences, Inc., Announces $13.9 Million Securities Offering
March 27, 2008
Oculus
Innovative Sciences Receives Chinese SFDA Regulatory Approval of Microcyn® Technology
March 17, 2008
Oculus
Innovative Sciences Announces Positive Results From Three Abstracts Evaluating
the Use of Microcyn® Technology in Diabetic Foot Ulcers
March 14, 2008
Oculus
Innovative Sciences Announces Additional Phase II Data for Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
March 12, 2008
Oculus
Innovative Sciences Announces Acceptance of Three Abstracts on the use of Microcyn® Technology
in Diabetic Foot Ulcers by DFCon 08
March 11, 2008
Oculus
Innovative Sciences to Announce Additional Phase II Data and Data from Two
Recent International Studies at DFCon 08
February 27, 2008
Oculus
Innovative Sciences Schedules Conference Call Today to Discuss Positive Top-Line
Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot
Ulcers
February 27, 2008
Oculus
Innovative Sciences Announces Positive Top-Line Phase II Data with Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
February 14, 2008
Oculus
Innovative Sciences to Present at the Roth Capital Partners 20th Annual OC
Growth Stock Conference
February 7, 2008
Oculus
Innovative Sciences Announces Fiscal Third Quarter 2008 Quarterly Results and
Clinical Update
February 5, 2008
Oculus
Schedules Fiscal Third Quarter 2008 Financial Results Release and Conference
Call
January 29, 2008
Oculus
Innovative Sciences Announces Agreement with Animal Health International for
North American Distribution of Microcyn®-Based Vetericyn™ Wound Spray
January 24, 2008
Oculus
Innovative Sciences Awarded Damages by Federal Court in Intellectual Property
Rights Litigation
January 22, 2008
Top-Line
Data from Oculus Innovative Sciences' Phase II Trial to Be Presented at DFCon
08 (Diabetic Foot Global Conference) on March 14, 2008
January 17, 2008
Oculus
Innovative Sciences, Inc. Appoints Gregg Alton to its Board of Directors
January 3, 2008
Oculus
Innovative Sciences Completes Patient Treatment and Follow-up in Its Phase
II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
December 18, 2007
Oculus
Innovative Sciences Announces Completion of Two Randomized Controlled Clinical
Trials of Microcyn® Technology in China
December 5, 2007
Oculus
Innovative Sciences Completes Enrollment of Phase II Trial of Microcyn® Technology
in Treatment of Mildly Infected Diabetic Foot Ulcers
November 19, 2007
Oculus
Innovative Sciences Wins Federal Court Ruling in Intellectual Property Rights
Litigation
November 12, 2007
Oculus
Innovative Sciences Announces Fiscal Second Quarter 2008 Quarterly Results
and Clinical Update
November 8, 2007
Oculus
Innovative Sciences Schedules Fiscal Second Quarter 2008 Financial Results
Release and Conference Call
November 1, 2007
Oculus
Innovative Sciences to Present at SMH Capital Markets Investor Growth Conference
More »
...........................................
|
Oculus Innovative Sciences
Niederlande B.V. (eine 100%ige Tochtergesellschaft von Oculus
Innovative Sciences, Inc.) wurde Ende 2003 gegründet.
Diese europäische Gesellschaft leitet die Vermarktung,
die Herstellung und den Vertrieb von Microcyn®-basierten
Produkten in Europa, Afrika und auf östlichen Märkten
und verfügt dank ihres Standorts in Sittard (im Südosten
der Niederlande) über einen strategisch günstigen
Zugang zu unseren Märkten. Die Region um Sittard zeichnet
sich durch eine ausgezeichnete wirtschaftliche Infrastruktur
und eine regionale Regierung aus, die die Biowissenschaft
bzw. technologie wahrhaftig schätzt.
Die europäische Gesellschaft konzentriert
sich darauf, die Wundpflege¬eigenschaften der höchst
innovativen Microcyn®-Technologie weithin bekannt zu
machen. Dermacyn® Wound Care ist eine superoxidierte
Lösung für die Behandlung von akuten und chronischen
Wunden (wie etwa diabetischen Fußgeschwüren
oder Verbrennungen). Dank der Kombination von ausgezeichneter
Leistung (weitläufig in der umfassenden Wundbehandlung
einsetzbar), beispielloser Sicherheit für Patienten, Ärzte
und Umwelt und einer einsatzbereiten, länger haltbaren
Formel ist Dermacyn® Wound Care zweifelsohne
ein revolutionäres
Produkt, das gemäß der europäischen Richtlinie
für Medizinprodukte (93/42/EEC) zugelassen wurde. Diese
CE-Zertifizierung wurde November 2004 erlangt.
Oculus Innovative Sciences Niederlande
verfolgt eine Marktakquisitionsstrategie, die ein regional
segmentiertes Vertriebsnetz nutzt. Nach der Einführung von Dermacyn® Wound
Care gegen Ende des Jahres 2004 erweitern wir derzeit dieses
Vertriebsnetz für die europäischen, afrikanischen und östlichen
Märkte.
For more information please contact:
Oculus Innovative Sciences
Netherlands B.V.
P.O. Box 5056
6130 PB Sittard
The Netherlands
Customer Service Europe
Telephone: +31- (46) - 4572 300
FAX: +31- (46) - 4572 399
Email: Info.europe@oculusis.com
|
